SEC Tracker
Get the app

LeonaBio

LONA

8 months of cash as of Jun 30, 2026 from the 10-Q on EDGAR

Get email alertsGet the app
Legal name
LeonaBio, Inc.
CIK
1620463
Sector
Biotech and pharma
  • Cash and short-term investments$51.1MCash and short-term investments up $21.2M vs the Jun 2025 quarter
  • Operating burn, last quarter$17.0MBurn up $10.0M vs the Jun 2025 quarter
  • Shares outstanding9.4M+139% from 3.9M on Aug 5, 2025, adjusted for the 1-for-10 reverse split by Nov 5, 2025

From the 10-Q 0001193125-26-352243 on EDGAR

Latest Net loss $19.0M, diluted EPS −$0.80 in the quarter ended Jun 30, 2026, from a 10-Q filed .

Dilution Known so far: no new shares beyond today's 9.4M · shelf room about $3.3M · not yet read: warrants, converts, options, ATM; 64.0M registered for resale, not counted. Every source

Insiders 1 insider bought $3K of LeonaBio stock on the open market in the last 90 days. Every trade

NotableSchedule 13D filed

Sermonix Pharmaceuticals reports a stake in LeonaBio

Read the Schedule 13D on EDGARTables over time

Cash runway and key numbers

About 2.7 quarters of cash at the average operating burn of the last 2 quarters, which would last to about Mar 2027.

Cash and short-term investments
$51.1M
Operating burn a quarter, average of the last 2 quarters
$18.9M

Operating burn by quarter: $20.9M in the Mar 2026 quarter, $17.0M in the Jun 2026 quarter; the runway uses their average, $18.9M.

From the 10-Q 0001193125-26-352243 for the period ended Jun 30, 2026, as tagged in its XBRL. An estimate from reported figures, not a forecast or advice.

Last quarter’s operating cash flow is the 6-month total in 0001193125-26-352243 less the 3-month total in 0001193125-26-211898.

Every quarter as a table
Key numbers, last 8 quarters (— means no figure was tagged for that quarter; each share count is the one on the report's cover, with the cover date under it; share counts are as each report filed them, not adjusted for later reverse splits, so a fall of more than half between quarters is usually a reverse split)
Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Cash and short-term investments$68.9M$51.3M$36.7M$29.8M$25.2M$88.3M$67.7M$51.1M
Quarterly burn$23.0M$26.0M$14.7M$7.0M$4.7M$19.4M$20.9M$17.0M
Shares outstanding38.7Mas of Nov 439.0Mas of Feb 2439.0Mas of May 639.4Mas of Aug 53.9Mas of Nov 59.3M9.4Mas of May 59.4Mas of Aug 4
R&D$17.9M$9.4M$4.3M$3.7M$2.8M$6.7M$11.3M$12.7M

Every line item over time, with Excel and CSV export

Get an email when LeonaBio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What LeonaBio does

LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). Source

Products

  • Lasofoxifene In development

    Lasofoxifene is a highly potent, orally bioavailable, small molecule, selective estrogen receptor modulator that inhibits estrogen receptor signaling in both wild-type and mESR1 breast cancer. Source

    Key ingredient: Selective estrogen receptor modulator

    • European Medicines Agency (Europe): withdrawn Source

  • ATH-1105 In development

    ATH-1105 is a novel, orally available, brain-penetrant, next generation, small-molecule drug candidate designed to positively modulate the neurotrophic HGF system. Source

    Key ingredient: Neurotrophic HGF system

  • ATH-1020 In development

    ATH-1020 is a novel, orally available, next generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system. Source

    Key ingredient: Neurotrophic HGF system

From the 10-K filed Mar 31, 2026, Item 1, Business (its first part). Open the filing. Each line links to the passage it restates. The company's own description, summarized; not investment advice.

All filings

Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.

Results, 8-Ks and key filings

  9. 4 older filings, Jun 23 to May 7

1 insider bought $3K of LeonaBio stock on the open market in the last 90 days. Every LONA insider trade

Financing and share filings

Other filings

Older filings on EDGAR

Shares registered for resale

Known so far: no new shares beyond today's 9.4M · shelf room about $3.3M · not yet read: warrants, converts, options, ATM.

64.0M registered for resale, already counted in today's shares where issued; 5.5M of them likely already outstanding.

Not read yet: warrants, convertible notes, options and RSUs and an ATM program.

What could become new LONA shares

Listing compliance

No listing notices in the 8-K item 3.01 filings SEC Tracker has read.

Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices

Trading halts

No trading halts for LONA since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.

Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts

Insiders

Show the latest Form 4 trade

Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. The Stake column is the change in their holding.

TradedInsiderTradeValueStakeNotes
Oct 26, 2026
Filed Oct 28, 2026
David J. Portman
10% owner
Open-market buy
3,149,470 shares
$3K
at $0.001
Their first shares, by the holdings the Form 4 states. Their first open-market buy here in SEC Tracker's records. The same day as the company's SCHEDULE 13D/A filed Oct 26, 2026.

Open-market buys and sales (Form 4 codes P and S); planned sales are marked under a Rule 10b5-1 plan. Values as stated in each Form 4. Not investment advice. Every Form 4 for LONA · Insider trades across companies

Fails-to-deliver: 182 shares on Aug 19, 2026, per SEC data

Coming up

  1. Earnings, expected
  2. 10-Q, expected (deadline Nov 16)

Stated dates are as each filing on EDGAR gives them; an expected date is estimated from the company's past filing dates, the same estimate as the top of the page. Not investment advice.

LeonaBio shares and listing

From the company's own filings; each row names its source. Not investment advice.

  • Shares outstandingas of Aug 4, 2026 (10-Q filed Aug 14)9.4Mwarrants, notes and options not read yet, so fully diluted is not known
  • Listing compliance8-K item 3.01No noticesin the filings read

Insider activity

1 insider bought $3K of LeonaBio stock on the open market in the last 90 days.

  • 10% owner bought $3K

All LONA insider trades

Stakes LeonaBio reports in other companies

Filings LeonaBio made as a holder or insider of another company. They are about that company, not LeonaBio.